文献速递衰弱、肌少症与跌倒

线粒体功能障碍与肌少症关联的遗传学证据:基于汇总数据的孟德尔随机化与共定位分析

Identification of Association Between Mitochondrial Dysfunction and Sarcopenia Using Summary-Data-Based Mendelian Randomization and Colocalization analyses.
PubMed 文献 · J Gerontol A Biol Sci Med Sci · 2025-01-01

结果识别出UQCC1(二级证据)和ETFDH(三级证据)两个与肌少症遗传相关的线粒体基因,提示其可能作为治疗肌少症的候选药物靶点。

要点

  • UQCC1表达升高与低握力风险增加相关(OR=1.114),并与步行速度下降相关。
  • ETFDH表达升高与四肢瘦体重降低及步行速度下降相关。
  • 两基因在骨骼肌组织中验证一致,可能成为肌少症候选药物靶点。

核心结论

  • UQCC1和ETFDH两个线粒体相关基因与肌少症存在遗传关联,提示线粒体功能障碍在肌少症发病中起重要作用。

主要发现

  • 整合3个肌少症相关性状分析后,识别出UQCC1(二级证据)和ETFDH(三级证据)两个与肌少症遗传相关的线粒体基因。
  • UQCC1表达升高增加低握力风险(OR=1.114;95%CI 1.078-1.152;P-FDR=1.70×10⁻⁷),并与步行速度呈负相关(Beta=-0.015;95%CI -0.021至-0.010;P-FDR=6.70×10⁻⁵)。
  • ETFDH表达升高与四肢瘦体重降低(Beta=0.031;95%CI 0.020-0.042;P-FDR=1.41×10⁻⁶)及步行速度下降(Beta=0.013;95%CI 0.006-0.021;P-FDR=0.029)相关。
  • 在骨骼肌组织中验证结果一致,提示发现具有稳健性。

关键数值与推荐

  • UQCC1与低握力关联的OR=1.114(95%CI 1.078-1.152),P-FDR=1.70×10⁻⁷。
  • UQCC1与步行速度关联的Beta=-0.015(95%CI -0.021至-0.010),P-FDR=6.70×10⁻⁵。
  • ETFDH与四肢瘦体重关联的Beta=0.031(95%CI 0.020-0.042),P-FDR=1.41×10⁻⁶。
  • ETFDH与步行速度关联的Beta=0.013(95%CI 0.006-0.021),P-FDR=0.029。

临床怎么用

  • UQCC1和ETFDH可作为肌少症潜在药物靶点,为未来干预研究提供遗传学依据。
  • 目前证据为遗传关联层面,尚不能直接用于临床基因筛查或治疗决策。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mitochondrial dysfunction has been demonstrated to be an important hallmark of sarcopenia, yet its specific mechanism remains obscure. In this study, mitochondrial-related genes were used as instrumental variables to proxy for mitochondrial dysfunction, and summary data for sarcopenia-related traits were used as outcomes to examine their genetic association. METHODS: A total of 1 136 mitochondrial-related genes from the human MitoCarta3.0 database were extracted. Genetic instruments for them were obtained from gene expression quantitative trait locus (eQTLs) study (n = 31 684). Aggregated data for sarcopenia-related traits including low hand grip strength (LHGS), appendiceal lean mass (ALM), and usual walking pace (UWP) were provided by large-scale genome-wide association studies (GWASs). We integrated eQTLs data with GWAS data to estimate genetic association between mitochondrial dysfunction and sarcopenia using summary-data-based Mendelian randomization (SMR) analysis. Additionally, we implemented colocalization analysis to strengthen their association. Finally, eQTLs data from skeletomuscular tissue (n = 706) was used to validate the primary findings. RESULTS: By integrating the analysis results from the 3 sarcopenia-related traits, 2 mitochondrial genes genetically associated with sarcopenia were identified, namely UQCC1 (tier 2 evidence) and ETFDH (tier 3 evidence). Specifically, elevated expression levels of UQCC1 increased LHGS risk (OR = 1.114; 95% CI, 1.078-1.152; P-FDR = 1.70 × 10-7), which matched the negative association between it and UWP (Beta = -0.015; 95% CI, -0.021 to -0.010; P-FDR = 6.70 × 10-5). Furthermore, elevated expression levels of ETFDH were found to be associated with both lower ALM (Beta = 0.031; 95% CI, 0.020-0.042; P-FDR = 1.41 × 10-6) and UWP (Beta = 0.013; 95% CI, 0.006-0.021; P-FDR = 0.029). Of note, consistent results were replicated in specific skeletomuscular tissues, further suggesting our findings were robust. CONCLUSIONS: Our analyses revealed the genetic association between 2 mitochondrial-related genes, ie, UQCC1 and ETFDH, and sarcopenia, highlighting the pivotal role of mitochondrial dysfunction driven by these genes in the pathogenesis of sarcopenia. Importantly, these candidate genes represent potential clinical drug targets for the treatment of sarcopenia.

来源:J Gerontol A Biol Sci Med Sci,查看原文。版权归原作者所有。

引用

  1. Xie J, Hao J, Xu X, et al. Identification of Association Between Mitochondrial Dysfunction and Sarcopenia Using Summary-Data-Based Mendelian Randomization and Colocalization analyses. J Gerontol A Biol Sci Med Sci. 2025. PMID: 39825753. doi:10.1093/gerona/glaf006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。